Exagen Inc. (XGN)
| Market Cap | 100.05M -54.0% |
| Revenue (ttm) | 72.30M +13.7% |
| Net Income | -18.17M |
| EPS | -0.76 |
| Shares Out | 24.23M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,356,970 |
| Open | 4.370 |
| Previous Close | 4.410 |
| Day's Range | 3.845 - 4.382 |
| 52-Week Range | 2.590 - 9.735 |
| Beta | 2.24 |
| Analysts | Strong Buy |
| Price Target | 9.43 (+128.31%) |
| Earnings Date | Nov 10, 2026 |
About XGN
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company’s lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CT... [Read more]
Financial Performance
In 2025, Exagen's revenue was $66.58 million, an increase of 19.65% compared to the previous year's $55.64 million. Losses were -$19.95 million, 32.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for XGN stock is "Strong Buy." The 12-month stock price target is $9.43, which is an increase of 128.31% from the latest price.
News
Exagen price target lowered to $9 from $11 at Roth Capital
Roth Capital lowered the firm’s price target on Exagen (XGN) to $9 from $11 and keeps a Buy rating on the shares. Excluding prior-period collections, the company’s Q3 revenues were…
Exagen price target lowered to $9 from $11 at Canaccord
Canaccord lowered the firm’s price target on Exagen (XGN) to $9 from $11 and keeps a Buy rating on the shares. The firm updated its model following Q3 results and…
Exagen price target lowered to $9 from $11 at Canaccord
Canaccord lowered the firm’s price target on Exagen (XGN) to $9 from $11 and keeps a Buy rating on the shares, citing reduced near- and long-term revenue estimates after the…
Exagen reports Q3 EPS (25c), consensus (17c)
Reports Q3 revenue $18.42M, consensus $18.34M. “Our third quarter extends what is fast becoming a record year for Exagen (XGN), and our ability to execute against our vision is increasingly…
Exagen backs FY26 revenue view $72M-$75M, consensus $73.91M
The company said, “The company reiterated full-year 2026 revenue guidance of $72 million to $75 million.”
Exagen files $150M mixed securities shelf
09:34 EST Exagen (XGN) files $150M mixed securities shelf
Exagen Earnings Call Transcript: Q3 2026
Q3 revenue rose 7% to a record $18.4M, while YTD adjusted EBITDA improved more than 30%. Guidance was reiterated as commercial productivity, Pharma Services and the myositis pipeline supported growth.
Exagen Earnings release: Q3 2026
Exagen released its Q3 2026 earnings on November 10, 2026, summarizing the period's financial results.
Exagen Slides: Q3 2026
Exagen has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 10, 2026.
Exagen Quarterly report: Q3 2026
Exagen has published its Q3 2026 quarterly earnings report on November 10, 2026.
Exagen Inc. Reports Third Quarter 2026 Financial Results
Third Quarter Revenue Grew 7% to $18.4 Million Year-to-Date Revenue Grew 11%, Net Loss Reduced by 12% and Adjusted EBITDA Loss Improved by Over 30% CARLSBAD, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) --...
Exagen Registration statement: Registration filing
Exagen filed a registration statement on November 10, 2026, providing details about a securities offering with the SEC.
Exagen Inc. to Participate in Upcoming Investor Conferences
Exagen will participate in the Canaccord Genuity MedTech & Diagnostics Conference November 11 and the Craig-Hallum Alpha Select Conference November 17
Exagen to Announce Third Quarter Financial Results on November 10, 2026
CARLSBAD, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2...
Exagen price target raised to $11 from $9 at Canaccord
Canaccord analyst Kyle Mikson raised the firm’s price target on Exagen (XGN) to $11 from $9 and keeps a Buy rating on the shares. The firm updated its model ahead…
Exagen price target raised to $11 from $10 at TD Cowen
TD Cowen analyst Dan Brennan raised the firm’s price target on Exagen (XGN) to $11 from $10 and keeps a Buy rating on the shares. The firm adjusted targets in…
Exagen transferred with Buy rating at B. Riley
B. Riley kept a Buy rating on Exagen (XGN) with a $12 price target following a transfer of coverage. The firm views Exagen as a “self-funded diagnostics turnaround,” transitioning to…
Exagen participates in a conference call with Craig-Hallum
Craig-Hallum holds a conference call with management on September 2 at 2 pm hosted by Craig-Hallum. Webcast Link
Exagen Transcript: Canaccord Genuity's 46th Annual Growth Conference
The company has significantly improved reimbursement rates and profitability by focusing on higher-quality test volume and operational efficiency. Product innovation continues with a new myositis test planned for 2027, while commercial expansion and R&D investment support long-term growth ambitions.
Exagen price target raised to $9 from $8 at BTIG
BTIG raised the firm’s price target on Exagen (XGN) to $9 from $8 and keeps a Buy rating on the shares. Exagen surged after a strong Q2 beat and raise,…
Exagen price target raised to $12 from $8 at B. Riley
B. Riley analyst Anderson Schock raised the firm’s price target on Exagen (XGN) to $12 from $8 and keeps a Buy rating on the shares. The firm cites higher estimates…
Exagen price target raised to $10 from $8 at TD Cowen
TD Cowen raised the firm’s price target on Exagen (XGN) to $10 from $8 and keeps a Buy rating on the shares. The firm said 2Q was solid with revenues…
Exagen price target raised to $9 from $8 at Canaccord
Canaccord raised the firm’s price target on Exagen (XGN) to $9 from $8 and keeps a Buy rating on the shares. The firm said the price target raise is driven…
Exagen raises FY26 revenue view to $72M-$75M from $70M-$73M
Consensus $71.67M. The company said, “The Company increased full-year 2026 revenue guidance to $72 million – $75 million compared to previous guidance of $70 million – $73 million.” Published first…
Exagen reports Q2 EPS (13c), consensus (17c)
Reports Q2 revenue $19.94M, consensus $17.87M. “We continue to advance Exagen’s (XGN) unique mission to bring clarity to autoimmune disease,” said John Aballi, President and Chief Executive Officer. “...